S'abonner

Plasmacytoid dendritic cells drive acute asthma exacerbations - 04/08/18

Doi : 10.1016/j.jaci.2017.08.032 
Aikaterini-Dimitra Chairakaki, PhD a, Maria-Ioanna Saridaki, MS a, Katerina Pyrillou, PhD a, Marios-Angelos Mouratis, PhD a, Ourania Koltsida, MD, PhD a, b, Ross P. Walton, PhD c, Nathan W. Bartlett, PhD c, d, Athanasios Stavropoulos, PhD a, Louis Boon, PhD e, Nikoletta Rovina, MD, PhD b, Nikolaos G. Papadopoulos, MD, PhD f, g, Sebastian L. Johnston, MD, PhD c, Evangelos Andreakos, PhD a,
a Department of Immunology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece 
b 1st Department of Respiratory Medicine, Medical School, National Kapodistrian University of Athens, “Sotiria” Regional Chest Diseases Hospital, Athens, Greece 
c Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom 
d Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia 
e Bioceros, Utrecht, The Netherlands 
f Institute of Human Development, University of Manchester, Manchester, United Kingdom 
g A. Kyriakou Children's Hospital, National Kapodistrian University of Athens, Athens, Greece 

Corresponding author: Evangelos Andreakos, PhD, Biomedical Research Foundation, Academy of Athens, Soranou Efesiou 4, Athens, Greece.Biomedical Research FoundationAcademy of AthensSoranou Efesiou 4AthensGreece

Abstract

Background

Although acute exacerbations, mostly triggered by viruses, account for the majority of hospitalizations in asthmatic patients, there is still very little known about the pathophysiologic mechanisms involved. Plasmacytoid dendritic cells (pDCs), prominent cells of antiviral immunity, exhibit proinflammatory or tolerogenic functions depending on the context, yet their involvement in asthma exacerbations remains unexplored.

Objectives

We sought to investigate the role of pDCs in allergic airway inflammation and acute asthma exacerbations.

Methods

Animal models of allergic airway disease (AAD) and virus-induced AAD exacerbations were used to dissect pDC function in vivo and unwind the potential mechanisms involved. Sputum from asthmatic patients with stable disease or acute exacerbations was further studied to determine the presence of pDCs and correlation with inflammation.

Results

pDCs were key mediators of the immunoinflammatory cascade that drives asthma exacerbations. In animal models of AAD and rhinovirus-induced AAD exacerbations, pDCs were recruited to the lung during inflammation and migrated to the draining lymph nodes to boost TH2-mediated effector responses. Accordingly, pDC depletion after allergen challenge or during rhinovirus infection abrogated exacerbation of inflammation and disease. Central to this process was IL-25, which was induced by allergen challenge or rhinovirus infection and conditioned pDCs for proinflammatory function. Consistently, in asthmatic patients pDC numbers were markedly increased during exacerbations and correlated with the severity of inflammation and the risk for asthma attacks.

Conclusions

Our studies uncover a previously unsuspected role of pDCs in asthma exacerbations with potential diagnostic and prognostic implications. They also propose the therapeutic targeting of pDCs and IL-25 for the treatment of acute asthma.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Plasmacytoid dendritic cells, asthma, animal models of allergic airway disease, rhinovirus, asthma exacerbations

Abbreviations used : AAD, BAL, BDCA-2, CRLF2, FITC, ILC2, MLN, ODN, OVA, OX40L, pDC, PDCA-1, Siglec-H, TLR, TSLP


Plan


 Supported by core funding from the Hellenic Ministries of Health and Education and by grant awards from the Hellenic Ministry of Education (“Thalis” Programme MIDAS and “Excellence” Programme RESOLVE-ASTHMA) and the European Commission (FP7 Programmes PREDICTA, NILTHERA and TACIT).
 Disclosure of potential conflict of interest: A.-D. Chairakaki has received grants from the European Commission and the Greek government (Ministry of Education and Religious Affairs). R. P. Walton is a board member/director for and has consultant arrangements with Therapeutic Frontiers. N. W. Bartlett has consultant arrangements with Abeome, is employed by Imperial College London and the University of Newcastle, has received grants from the Medical Research Council and Abeome, is an inventor on US nonprovisional patent 30817 owned by Abeome, has received stock options from Abeome, and has received travel support from Abeome. N. Rovina has participated in advisory boards for Novartis, AstraZeneca, Chiesi, and Menarini and has received payment for lectures from Chiesi, Novartis, Elpen, and Boehringer. N. G. Papadopoulos has board memberships with Novartis, Faes Farma, Biomay, HAL, and Nutricia Research; has consultant arrangements with Menarinin, Novartis, and MEDA; has received grants from Menarini; and has received payment for lectrues from Abbvie, Novartis, MEDA, MSD, MEDA, Omega Pharma, and Danone. S. L. Johnston has received grants from Centocor, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, and Synairgen; has received personal fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Synairgen, Aviragen, Bayer, Concert Pharmaceuticals, and Myelo Therapeutics; is co-owner of a patent with Sanofi Pasteur; is a shareholder in Synairgen; is director and a shareholder in Therapeutic Frontiers; has a patent (Blair ED, Killington RA, Rowlands DJ, Clarke NJ, Johnston SL. Transgenic animal models of HRV with human ICAM-1 sequences. UK patent application no. 02 167 29.4 [July 18, 2002] and International patent application no. PCT/EP2003/007939 [July 17, 2003], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application no. GB 0405634.7 [March 12, 2004], licensed), has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for anti-virus therapy for respiratory diseases. International patent application no. PCT/GB05/50031 [March 12, 2004], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. The use of interferon lambda for the treatment and prevention of virally-induced exacerbation in asthma and chronic pulmonary obstructive disease. UK patent application no. 0518425.4 [September 9, 2005], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. US patent application 11/517,763, patent no. 7569216, National Phase of PCT/GB2005/050031 [August 4, 2009], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. European patent no. 1734987 [May 5, 2010], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNb therapy]. Hong Kong patent no. 1097181 [August 31, 2010], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNb therapy]. Japanese patent no. 4807526 [August 26, 2011], licensed); has a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. New Hong Kong–divisional patent application no. 11100187.0 [January 10, 2011], licensed); and has a patent (Burdin N, Almond J, Lecouturieir, V, Girerd-Chambaz Y, Guy, B, Bartlett N, Walton R, McLean G, Glanville N, Johnston SL. Induction of cross-reactive cellular response against rhinovirus antigens. European patent no. 13305152 [April 4, 2013], pending). E. Andreakos has received grants from the European Commission and the Greek Ministry of Education and Religious Affairs. The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 2

P. 542 - août 2018 Retour au numéro
Article précédent Article précédent
  • Fibrinogen cleavage products and Toll-like receptor 4 promote the generation of programmed cell death 1 ligand 2–positive dendritic cells in allergic asthma
  • Minkyoung Cho, Jeong-Eun Lee, Hoyong Lim, Hyun-Woo Shin, Roza Khalmuratova, Garam Choi, Hyuk Soon Kim, Wahn Soo Choi, Young-Jun Park, Inbo Shim, Byung-Seok Kim, Chang-Yuil Kang, Jae-Ouk Kim, Shinya Tanaka, Masato Kubo, Hui-Ying Tung, Cameron T. Landers, David B. Corry, Farrah Kheradmand, Yeonseok Chung
| Article suivant Article suivant
  • A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation
  • Paul Engeroff, Marc Fellmann, Daniel Yerly, Martin F. Bachmann, Monique Vogel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.